Next Article in Journal
Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability
Next Article in Special Issue
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
Previous Article in Journal
The Role of HSPB8, a Component of the Chaperone-Assisted Selective Autophagy Machinery, in Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 10
Issue 2
10.3390/cells10020336
Review Report
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications

Cells 2021, 10(2), 336; https://doi.org/10.3390/cells10020336
by Ignacio J. Cardona-Benavides 1,2,†, Cristina de Ramón 1,2,† and Norma C. Gutiérrez 1,2,3,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Cells 2021, 10(2), 336; https://doi.org/10.3390/cells10020336
Submission received: 13 January 2021 / Revised: 28 January 2021 / Accepted: 1 February 2021 / Published: 5 February 2021
(This article belongs to the Special Issue Molecular and Cellular Mechanisms of Cancers: Multiple Myeloma 2020)

Round 1

Reviewer 1 Report

The authors widely described the genetic abnormalities in multiple myeloma focusing on prognostic and therapeutic aspects. 

The paper lacks of an esplicative figure showing the involvement of each abnormalities in the progression of the disease through different stages (MGUS, SMM, MM. In particular, it should be useful to indicate primary and secondary genetic events in each stage. 

Moreover, the authors should summarize in a table the mechanisms of resistance to different drugs associated with genetic abnormalities. This aspect is reported in the text but should be highlighted in a table. 

Lastly, since the authors mentioned different drugs currently used or in clinical trial, they should add a figure showing the main mechanisms of these drugs 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

This is a well written review on genetics in myeloma covering the major mechanisms of alterations, their prognosis and how treatments can change the unfavourable outcomes. It is split in 3 parts : translocations, copy number alterations and mutations. The references are exhaustive.

Minor revisions :

  • I would add one table summarizing the prognosis per se for each abnormalities showing the differences between the Mayo stratification, the IFM and the IMWG in terms of definitions of high, intermediate and standard risk. Moreover, in reference to the recently published paper by J Corre and H Avet Loiseau in Blood 2020, i would discuss why genomic risk is currently changing.
  • The threshold for 17p del is 50-60% for the IFM
  • Double hit myeloma is not only ISS3 with 1q ampl, it involves also del 17p. Give a better definition
  • Table 1 : What is alo ? allogeneic transplantation ?
  • present horizontally

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

I thank the authors for your complete reply

Back to TopTop